An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1

详细信息    查看全文

• 作者：John Cogswell ; H. David Inzunza ; Qiuyan Wu ; John N. Feder…
• 刊名：Molecular Diagnosis & Therapy
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：21
• 期：1
• 页码：85-93
• 全文大小：2125KB
• 刊物主题：Molecular Medicine; Human Genetics; Cancer Research; Laboratory Medicine; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-2000
• 卷排序：21

文摘

AimNivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non–small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in the USA and EU for advanced melanoma, NSCLC, and RCC, and relapsed Hodgkin lymphoma in the USA. Programmed death-ligand 1 (PD-L1), a PD-1 ligand, is expressed on mononuclear leukocytes, myeloid cells, and tumor cells. PD-L1 is being investigated as a potential biomarker to predict the association of tumor PD-L1 expression with nivolumab efficacy.